An FDA panel wants unapproved peptides sold by prescription. That is deregulation, not wellness.

An FDA advisory panel has voted to increase consumer access to several peptides, recommending that products marketed for sleep issues, wound healing, cognitive disorders and other uses be available through compounding pharmacies with a prescription ^[2][4]. The consequence is not a new supplement aisle: it is a decision to move part of a multibillion-dollar gray market inside the prescription system without first requiring the human testing that the prescription system exists to enforce ^[5][9].

Start with the mechanism, because the mechanism is the whole story. Compounding pharmacies make customized medications, are subject to less oversight than traditional pharmacies, and can distribute drugs that have not been FDA approved ^[3]. Routing a compound through them converts a product with no approval into a product with a prescription, which is exactly the signal most patients read as evidence that someone checked.

Today those same molecules move a different way. Untested peptides are widely available online from loosely regulated manufacturers ^[6], frequently sold with a "research use only" label that functions as a loophole around the oversight applied to approved drugs ^[7]. The FDA has gone after companies that explicitly advertised and sold such products for human use ^[8]. Scientists say many peptides in this market are sold without human-safe manufacturing processes and without human testing to show they work ^[5]. A prescription channel does not fix either gap; it relocates it.

The scale is worth holding onto. The FDA has approved roughly 100 peptides for therapeutic use against specific conditions such as diabetes and multiple sclerosis ^[10], and in July the advisory panel took up seven unapproved ones ^[18]. Those seven amount to about 7 percent of the entire approved peptide catalogue by count, added without the trials the other 100 had to run ^[20]. Insulin, the first synthetically manufactured peptide ^[13], and the GLP-1 agonists sold as Ozempic and Wegovy ^[14] got there through years of rigorous trials, which is what approval requires ^[15]. "Only a few peptides are actually FDA approved meaning they are safe and efficacious for certain diseases," Jonathan Long, a peptide researcher and associate professor of pathology at Stanford University, told Live Science by email. "Many other peptides are still not FDA approved and should be considered experimental" ^[16].

The category confusion helps the sellers. Peptides are simply short chains of amino acids, smaller and structurally simpler than proteins ^[11], and about 7,000 known ones already run ordinary business inside the body, including insulin, oxytocin, vasopressin and endorphins ^[12]. That biological ubiquity gets marketed as safety. Legally, though, anything intended to treat disease or alter the structure or function of the body is a drug and should be approved for safety and effectiveness ^[9]. Only plant- and food-derived peptides such as collagen sit in the supplement bucket, where potency and purity vary more than in approved drugs ^[19]. Opponents of the panel's vote argue precisely that the products in question have not been through rigorous clinical testing and could pose risks ^[17].

Watch whether the agency adopts the panel's recommendation, and whether the current "research use only" sellers reposition as prescription suppliers rather than exiting ^[7]. Watch also whether FDA enforcement against human-use marketing continues once a lawful human-use channel exists ^[8], and note that peptides are being promoted publicly by Health and Human Services Secretary Robert F. Kennedy Jr., which sets the political weather for any decision ^[1].